Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials

• Published in: Journal of neurology Vol. 269; no. 1; pp. 205 - 216
• Main Authors: Fatemeh, Gholami, Sajjad, Moradi, Niloufar, Rasaei, Neda, Soveid, Leila, Setayesh, Khadijeh, Mirzaei
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2022; Springer Nature B.V
• Subjects: Adult; Clinical trials; Dietary Supplements; Humans; Medicine; Medicine & Public Health; Melatonin; Melatonin - therapeutic use; Mental disorders; Meta-analysis; Metabolic disorders; Neurodegenerative diseases; Neurology; Neuroradiology; Neurosciences; Randomized Controlled Trials as Topic; Respiratory diseases; Review; Sleep; Sleep disorders; Sleep Quality; Sleep Wake Disorders - drug therapy; Supplements; United States > US; Sleep quality; Melatonin; PSQI; Meta-analysis
• ISSN: 0340-5354; 1432-1459; 1432-1459
• DOI: 10.1007/s00415-020-10381-w

Background The Present study was conducted to systematically review the effect of the melatonin on sleep quality. We summarized evidence from randomized clinical trials (RCTs) that investigated the effects of melatonin on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) in adults with various diseases. Methods The literature searches of English publications in MEDLINE and EMBASE databases were performed up June 2020. Results were summarized as mean differences (MD) with 95% confidence intervals (CI) using random effects model (DerSimonian–Laird method). Heterogeneity among studies was evaluated by the Cochrane Q test and I-squared (I2). To determine the predefined sources of heterogeneity, subgroup analysis was performed. Results Of 2642 papers, 23 RCTs met inclusion criteria. Our results indicated that melatonin had significant effect on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) (WMD: − 1.24; 95% CI − 1.77, − 0.71, p  = 0.000). There was significant heterogeneity between studies ( I 2  = 80.7%, p  = 0.000). Subgroup analysis based on health status and kind of intervention were potential between-study heterogeneity. Subgroup analysis based on health status revealed melatonin intervention in subjects with Respiratory diseases (WMD: − 2.20; 95% CI − 2.97, − 1.44, p  = 0.000), Metabolic disorders (WMD: − 2.74; 95% CI − 3.48, − 2.00, p  = 0.000) and sleep disorders (WMD: − 0.67; 95% CI − 0.98, − 0.37, p  = 0.000) has significant effect on sleep quality. Conclusion We found that the treatment with exogenous melatonin has positive effects on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) in adult. In adults with respiratory diseases, metabolic disorders, primary sleep disorders, not with mental disorders, neurodegenerative diseases and other diseases.